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eHealth is a broad term with many defini-
tions, including health informatics, health
telematics, ICT (information and commu-
nication technology) for health, connected
health, medical computing, or medical
informatics, all of which are used to
describe the use of a wide range of infor-
mation technology applications and
services in the healthcare setting. For the
‘Legally eHealth’∗ study described in this
article we use the term eHealth as defined
by the Action Plan for a European eHealth
Area: “the application of information and
communication technologies across the
whole range of functions that affect the
health sector”.1
eHealth is premised on a fundamentally
new patient experience unconstrained by
familiar points of entry and structures or
traditional channels for delivering infor-
mation or care. Not surprisingly therefore,
the eHealth revolution has as many serious
implications for health care regulators and
lawyers as for medical professionals,
including questions about patient and
professional identification, maintenance of
patient confidentiality in an environment
of electronically shared care, as well as
questions of liability for care provided in
this new environment.
In response to the lack of legal certainty
about the use of eHealth tools, the
European Commission, through its
eHealth Action Plan, called for a study to
establish a base-line report on existing EU
level legislation, its impact on the delivery
of eHealth and an analysis of the legal gaps
which may exist. The ‘Legally eHealth’
study, which we present in this article, was
completed in response to that call.
The ‘Legally eHealth’ Framework
The one year study, completed in May
2007, looked in detail at three particular
legal aspects of using information society
technologies (IST) in health care: privacy,
liability and competition. Although other
legal issues arise in the context of
providing health care services using
eHealth tools, we focussed on these three
as the main legal issues with European
level implications. 
We first looked at the key tools and appli-
cations and then the main stakeholders and
existing regulations that have an impact on
the use of eHealth. These covered a wide
range of information technologies found in
hospitals and primary care settings,
including administrative tools such as
hospital information systems (HIS),
summary records and discharge letters;
clinical applications of a technical nature
such as picture archiving and communica-
tions systems (PACS), as well as clinical
support systems such as operating theatre
systems (OR), decision support systems
(DSS); and systems linking key health care
actors such as General Practitioners
Systems, and electronic prescribing
systems linking general practitioners (GPs)
with pharmacies (eRx). 
Having established what concepts and
tools were included in eHealth, we next
classified the stakeholders in eHealth into
four groups of actors: citizens and patients;
clinicians and care providers; payers,
policy-makers and governments; and,
vendors, suppliers and commercial
partners. All four groups of actors have
highly significant but not always equal
roles to play in health care. We looked in
particular at the tensions that can arise
between clinicians and patients with
respect to privacy and confidentiality, or
between governments and vendors with
respect to competition in the health care
market.
The study considered the impact of
European data protection legislation,
European consumer protection and
liability legislation, and European compe-
tition law. We analysed this legislation in
detail, and followed the analysis by a series
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of small case study ‘vignettes’ which
demonstrated the practical implications of
the key legal concepts. Key legal aspects
studied in the ‘vignettes’ included:
Electronic Medical Records
– responsibility of the service provider to
the physician
– responsibility of the physician to
his/her patients
Sale of medical products on line
– responsibility of the manufacturer's
website
– responsibility of the consumer
Distance monitoring products
– responsibility of the manufacturer, 
– responsibility of the service provider
Using digital records pedagogically
– protecting patient anonymity
eHealth industry
– role of the state versus private sector
– monopoly and competition 
We concluded with recommendations to
the European Commission on further
regulatory activities to support the imple-
mentation of eHealth. 
In this article we outline the three legal
aspects we studied and the key recommen-
dations made. 
On data protection
The study looked in detail at the require-
ments of EU privacy and data protection
legislation, providing a thorough exami-
nation of the Data Protection Directive
(95/46/EC) and the Directive on Privacy in
Electronic Communications (2002/58/EC). 
We looked carefully at the existing regula-
tions and concluded that while the Direc-
tives are probably sufficient to meet the
needs of IST in health, further clarification
of specific legal duties would be helpful.
Data protection legislation is now well
established in Europe: while health data is
always sensitive and requires special
protection, such data may be processed on
the basis of patient consent; or in the vital
interests of the patient; or for the purpose
of medical diagnosis and care provision; or,
in certain cases, if there is a substantial
public interest in such data processing. 
We believe that generally the existing data
protection legislation at EU level and its
transposition at Member State level are
sufficient to allow eHealth tools and appli-
cations to be used efficiently in health care.
However, we recommended that the
European Commission and Member States
cooperate, in particular through the Data
Protection Working Party set up under
Article 29 of the Data Protection
Directive, to address uncertainties in the
role of consent to the processing of
medical data; the necessity to state a
finality of purpose for data collection; and
technical aspects of data processing and
storage security.
There are particular difficulties connected
with the concept of ‘consent’ in health
related data processing. A particular
problem with consent lies in the fact that,
in order to be valid, consent must be freely
given. Thus, if the creation of electronic
medical records is a necessary and
unavoidable aspect of providing good
quality health care, then withholding
consent may be to the patient’s detriment.
We argue therefore that it would seem
appropriate for the European Commission
to coordinate the adoption of specific rules
for the processing of health information
that allows for proper balancing of
patients’ and public health interests,
without recourse to the concept of consent.
On eHealth and product liability
Traditionally, medical liability is restricted
to the relationship between the patient and
the health practitioner (usually a doctor).
When a patient is a victim of medical negli-
gence or of a medical error, he or she will
usually seek to introduce a civil or criminal
lawsuit against the doctor. However, the
use of eHealth tools, as well as the multi-
plication of intermediaries in the field of
health services, is changing the legal rela-
tionships between the various actors, and
often makes it more difficult for a patient
to know where liability lies if something
goes wrong. 
Although general legal rules have been
agreed to provide consumers with a legal
guarantee of high quality products and
services, the legal texts do not specifically
address health or eHealth. The current EU
level law is applied within the general
context of service provision and product
delivery, whether by traditional or elec-
tronic means. As a result it is often difficult
to ascertain which EU level legislation
applies to an eHealth product: is it
considered a medical device, a software
package, and does other legislation (for
example, on hazardous substances) also
apply? In terms of health goods, whether
eHealth or traditional, standard contracts
for sale of goods will apply. In general
therefore in the eHealth arena, the
purchaser of an eHealth good will need to
make reference to the relevant national
legislation based on Directive 1999/44/EC
on the Sale of Consumer Goods. 
The study concluded that while specific
eHealth sale of goods legislation is
probably not needed, it might be appro-
priate to consider the adoption of specific
EU level guidelines on the sale of eHealth
goods in order to encourage the adoption
of EU wide markets in eHealth tools
rather than the fragmented national level
markets one sees currently.
Beyond the sale of the product, Directive
2001/95/EC on General Product Safety
requires that any product put on the
market for consumers, or likely to be used
by them, is safe. Further it requires that
producers provide consumers with the
relevant information enabling them to
assess the risks inherent in the product,
and take appropriate actions to avoid these
risks (withdrawal from the market,
warning to the market consumers, recall
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products already supplied etc). 
National authorities have been established
to monitor product safety and to take
appropriate measures to protect
consumers and an information system has
been put in place which imposes collabo-
ration not only between distributors,
producers and the national authorities but
also between Member States and the
European Commission (RAPEX).2 This
system has thus far not been used well (if at
all) for eHealth products, which are still
rather new and for which little legal
guidance currently exists. Accordingly, the
study recommended that the European
Commission should adopt policy tools to
encourage the use of the RAPEX system
for eHealth products. 
We also noted also that some eHealth
products are considered medical devices,
in the terms of Directive 93/42/EC on
Medical Devices. The Directive includes in
its definition of medical devices electronic
equipment and software manufactured or
promoted for medical purpose. Thus,
monitoring devices, for example, could be
considered as medical devices under the
European Medical Device legislation,
while eHealth tools used for the adminis-
tration of general patient data will
generally not be considered medical
devices unless such a product (for example,
a laptop, printer, screen, etc.) has had a
specific medical purpose assigned to it. 
It is clear that more clarity is needed on the
extent to which eHealth products are
covered by Medical Devices Legislation.
Many of the currently available moni-
toring devices are covered only by general
product liability, not by a specific liability
provision. It is suggested that further
consultation on the application of medical
devices legislation to eHealth tools takes
place to establish if special guidelines
should be issued.
On competition law
Health services, in most European coun-
tries, are provided at least to some extent
though direct taxation and compulsory
health insurance. However, most eHealth
services are offered through private enter-
prises and businesses and thus eHealth
poses difficult questions concerning
competition within public and private
markets in situations where the distinction
between the two is often very hard to
establish.
The principles of free trade and free
competition are among the most important
economic principles supported by the
European Community. It is therefore not
surprising that the European Community
has adopted a wide range of legislation to
support free competition through a legal
system that prohibits any disloyal practices
that restrict competition. 
The core of European competition law is
found in the rules applying to private firms
or ‘undertakings’ in Articles 81 and 82.
Article 81 prohibits agreements and
concerted practices with an anticompet-
itive objective or effect on the market,
while Article 82 prohibits abuse of a
dominant position. Article 86(2) states that
the rules on competition also apply to
public undertakings, as long as the “appli-
cation of such rules does not obstruct the
performance, in law or in fact, of the
particular tasks assigned to them.” 
The rules of competition law on abuse of
dominant position and concerted practices
are defined by the Treaty to apply only to
those organisations classified as ‘under-
takings’. The key question for purposes of
health care providers is therefore whether
any of the parties to an eHealth service are
deemed to be undertakings and therefore
subject to competition law.
Recent case law at national and EU level3
has established that publicly funded health
bodies may, in certain circumstances, be
subject to competition law. However, the
case law is unclear and would seem to
provide that the same institution may, in
some aspects of its conduct, be regarded as
an undertaking (if it offers goods or
services on the market) but in other aspects
(such as contracting out certain care
services) will not be considered an under-
taking. 
This ambiguity in law will be unsettling for
both public and private sector health care
providers. The study recommended,
therefore, that the appropriate committees
of the European Commission should be
encouraged to examine the recent decisions
of the European Court of Justice (ECJ) on
the application of Articles 81 and 82 to
health care providers, in order to draw up
clear guidelines establishing when a health
care provider will be regarded as an under-
taking and when not. Such guidelines
should address the widest possible range of
health care providers and suppliers,
covering traditional and eHealth care.
Further to Article 86(2), the Treaty
provides that an undertaking normally
subject to the rules of competition law may
be exempted from their application if it has
been entrusted by a public body to provide
a Service of General Economic Interest
(SGEI)4 and if the application of the rules
on competition would obstruct the
performance of the particular tasks
assigned to them. While it is left up to
Member States to define the services they
consider as SGEI, considerable lack of
clarity still exists at EU level on the desig-
nation of health services.
Recognising that many European health
systems are provided through public
funds, the European Commission has, in a
number of communications, suggested that
health services are not generally to be
regarded as SGEI nor are they to be
included in the wider definitions of
Services of General Interest (SGI) or Social
Services of General Interest (SSGI)*. The
Commission has instead proposed that,
because health services have such a unique
character, special targeted rules on health
services of general interest should be estab-
lished. However, despite first raising this
issue in 2001, the European Commission
has yet to clarify the position of health
services and their possible exemption from
competition law.
The study recommended that the
Commission adopt a communication or
guidelines setting out clearly the circum-
stances under which a health service
provider may make use of the provisions
on SGEI in the Treaty and thus be
exempted from competition law. Such
guidelines should address the changing
nature of health services, recognising that a
wide range of actors from both public and
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* For the evolution of the definition on Services of General Interest, see Green and White Papers at 
http://europa.eu/eur-lex/en/com/gpr/2003/com2003_0270en01.pdf  (COM(2003) 270 final, May 2003) and 
http://europa.eu/eur-lex/en/com/wpr/2004/com2004_0374en01.pdf (COM(2004) 374 final, May 2004), announcing a more systematic
approach in the field of social and health services of general interest. This systematic approach is proposed by a Communication from
the Commission ‘Implementing the Community Lisbon programme: Social services of general interest in the European Union’
(COM(2006)177, April 2006), available at http://ec.europa.eu/employment_social/social_protection/docs/com_2006_177_en.pdf. 
For more information, see http://ec.europa.eu/employment_social/social_protection/questionnaire_en.htm.)
private enterprises will be involved in the
provision of both traditional and eHealth
services. In order to encourage adequate
investment in eHealth services, both public
and private enterprises must have legal
certainty on their position with respect to
competition law. 
Conclusion
eHealth is important for Europe, it can
drive up service quality, improve patient
safety, contain costs and facilitate access to
health care. The ‘Legally eHealth’ study
has examined aspects of European law
related to data protection, liability and
consumer protection, and competition law.
It has identified that a significant body of
European law already addresses a number
of the key legal issues in eHealth.
However, there is still great uncertainty in
the eHealth actors, ranging across public
bodies, big industry and small enterprises
about the full legal implication of using
and offering eHealth services. 
It is notable that despite the large numbers
of communications on Services of General
Interest, the Lisbon agenda and long-term
care, as well as heated debates on health
services with the Services Directive, little
emphasis has been given to an impact
assessment of the proposed legislative
responses to health services in general.
Moreover, none have considered in depth
their impact on eHealth services. Given
however, that the development of eHealth
markets is considered to have major
economic potential for Europe,5 further
legal clarifications are necessary both to
encourage the development of these
markets in optimal conditions, all the
while respecting the unique nature of
health services. Therefore, in addition to
the specific recommendations made on
each of the three clusters of legal issues, the
study calls for a mainstreaming of eHealth
impact assessment across all European
policy initiatives.
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Summary: The development of nanotechnology has huge potential for medical science. However at
the same time it gives rise to a range of legal and ethical regulatory challenges for the EU and
Member States. This paper explores first what is meant by nanotechnology and its use in medicine.
Secondly, it considers some of the ethical and regulatory challenges discussed  by the European
Group on Ethics in Science and New Technologies in their recent Opinion on the ethical aspects of
nanomedicine. It suggests that there are many legal and ethical issues which will need to be further
explored at both EU and Member State level, including the diversity of current regulatory 
structures applicable in this area, issues of consent, privacy and the regulation of risk. 
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The rise of nanotechnology in general and
nanomedicine in particular has led to
considerable debate and controversy.1
‘Nanotechnology’ can enable us to better
understand how the body functions at
molecular level. ‘Nano’ itself refers to ‘one
billionth’ and originates from the Greek
word meaning ‘dwarf’. As the European
Technology Platform Report comments:
“It is an extremely large field ranging from
in vivo and in vitro diagnostics to therapy
including targeted delivery and regener-
ative medicine. It has to interface nanoma-
terials (surfaces, particles or analytical
instruments) with ‘living’ human material
(cells, tissues and body fluids). It creates
new tools and methods that impact signif-
icantly on existing conservative prac-
tices”.2
The development of this technology may
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